ויזודיין - Visudyne
ש××× ×× !
×ת×ר××: 5.11.2018 ×תק××× ××××¢× ×× ×©×××ק ×תר××¤× ××פסק ×צ××ת×ת.
×ת×ר××: 5.11.2018 ×תק××× ××××¢× ×× ×©×××ק ×תר××¤× ××פסק ×צ××ת×ת.
×ק×ר: ××©×¨× ××ר×××ת - ××××¢×ת ×¢× ×פסקת ש×××ק תר×פ×ת
× ×ª×× × ×ª×¨×פ×
×××¨×©× 
| ק×××¦× ×¤×¨×ק×××××ת (ATC4) | S01LA Antineovascularisation agents | |||||
|---|---|---|---|---|---|---|
| ×ר××× ×¤×¢×× (ATC5) | Â
| |||||
| צ×רת ××ª× | ת××-×ר××× - I.V | |||||
| צ×רת ××× ×× | ×××§× ×××× ×ª ת×××¡× ×××× ×¤××××, POWDER FOR SOLUTION FOR INFUSION ××× ×עת ××× ×× ×תר ×× ×רע×× ×ש ××××× ×ת ×תר××¤× ××ת×× ×××× ×× ××××××¥ ××¤× ×©××פ××¢ ××¢××× ×צר×× | |||||
| ×ת×××× | Visudyne is indicated for the treatment of patients with predominantly classic or occult subfoveal choroidal neovascularization due to age related macular degeneration, or with subfoveal choroidal neovascularization caused by other macular diseases.
| |||||
× ×ª×× × ×¡× [ ×צ×× ]
| ||||||
| ×¢××× ×ר××¤× ××××ר×ת ××¢××× |
××× ×¢××× ×ר××¤× | |||||
| ×¢××× ×צר×× |  |
|---|
| ער××× ××××ק×רפ××× | ער××× ×§×©×ר×× ××××ק×רפ××× |
|---|---|
| [ ××××××××] ××××ר ××©×¨× ××ר×××ת |
| ××פ×ש ×××ר×× | ×××ר×× ×-PubMed |
|---|---|
| ××××¢ ×רשת | RxList WebMD Drugs.com |
| ×©× ××¦×¨× | PAR STERILE PRODUCTS LLC, USA |
| ×©× ××¢× ×ר×ש×× | NOVARTIS ISRAEL LTD |
| ר×ש××× | ת×ר×× ××ש×: 08/2000. ר×ש××× ×ת×ר××: 10/2010 |
| ת×ר×× ×¢×××× ××ר×× | 5.11.2018 |